Literature DB >> 9500194

TTF-1 protein expression in pleural malignant mesotheliomas and adenocarcinomas of the lung.

C Di Loreto1, F Puglisi, V Di Lauro, G Damante, C A Beltrami.   

Abstract

TTF-1 is a tissue-specific transcription factor expressed in the epithelial cells of thyroid and lung. This study investigates the immunohistochemical expression of TTF-1 in pleural malignant mesotheliomas (MM) and adenocarcinomas (AC) of the lung, respectively. For this purpose, 33 biopsy specimens of pulmonary AC and 24 specimens of MM were studied. TTF-1 immunoreactivity was identified in 19 of 33 cases of AC (57.5%) and in none of the 24 cases of MM. Positivity for TTF-1 was 100% specific and 57.5% sensitive for lung AC. Alternatively, negativity for TTF-1 was 57.5% specific and 100% sensitive for MM. These results suggest that TTF-1 can be favourably added to the immunohistochemical diagnostic panel for distinction between AC of the lung involving the pleura and pleural MM.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9500194     DOI: 10.1016/s0304-3835(97)00466-7

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  11 in total

1.  Recommendations for the reporting of pleural mesothelioma.

Authors:  Kelly J Butnor; Thomas A Sporn; Nelson G Ordonez
Journal:  Virchows Arch       Date:  2006-11-25       Impact factor: 4.064

2.  My approach to the diagnosis of mesothelial lesions.

Authors:  K J Butnor
Journal:  J Clin Pathol       Date:  2006-06       Impact factor: 3.411

Review 3.  Guidelines for the diagnosis and treatment of malignant pleural mesothelioma.

Authors:  Nico van Zandwijk; Christopher Clarke; Douglas Henderson; A William Musk; Kwun Fong; Anna Nowak; Robert Loneragan; Brian McCaughan; Michael Boyer; Malcolm Feigen; David Currow; Penelope Schofield; Beth Ivimey Nick Pavlakis; Jocelyn McLean; Henry Marshall; Steven Leong; Victoria Keena; Andrew Penman
Journal:  J Thorac Dis       Date:  2013-12       Impact factor: 2.895

4.  ALK rearrangement in specific subtypes of lung adenocarcinoma: immunophenotypic and morphological features.

Authors:  Luciana Possidente; Matteo Landriscina; Giuseppe Patitucci; Ludovica Borgia; Vittoria Lalinga; Giulia Vita
Journal:  Med Oncol       Date:  2017-03-31       Impact factor: 3.064

5.  Expression of thyroid transcription factor-1 in malignant pleural effusions.

Authors:  Andras Khoor; Angela L Byrd-Gloster; Santo V Nicosia
Journal:  Pathol Oncol Res       Date:  2010-09-17       Impact factor: 3.201

6.  [Pseudo-mesotheliomatous adenocarcinoma of the lung].

Authors:  K Aumann; J Günter; N Freudenberg
Journal:  Pathologe       Date:  2010-07       Impact factor: 1.011

7.  Re-evaluation of histological diagnoses of malignant mesothelioma by immunohistochemistry.

Authors:  Helmut P Sandeck; Oluf D Røe; Kristina Kjærheim; Helena Willén; Erik Larsson
Journal:  Diagn Pathol       Date:  2010-07-06       Impact factor: 2.644

8.  Molecular determination of the clonal relationships between multiple tumors in BRCA1/2-associated breast and/or ovarian cancer patients is clinically relevant.

Authors:  Willemina R R Geurts-Giele; Victorien M T van Verschuer; Carolien H M van Deurzen; Paul J van Diest; Rute M S M Pedrosa; J Margriet Collée; Linetta B Koppert; Caroline Seynaeve; Winand N M Dinjens
Journal:  Mod Pathol       Date:  2016-09-09       Impact factor: 7.842

Review 9.  Nkx2-1: a novel tumor biomarker of lung cancer.

Authors:  Li Yang; Min Lin; Wen-jing Ruan; Liang-liang Dong; En-guo Chen; Xiao-hong Wu; Ke-jing Ying
Journal:  J Zhejiang Univ Sci B       Date:  2012-11       Impact factor: 3.066

10.  Immunohistochemistry in the distinction between malignant mesothelioma and pulmonary adenocarcinoma: a critical evaluation of new antibodies.

Authors:  A S Abutaily; B J Addis; W R Roche
Journal:  J Clin Pathol       Date:  2002-09       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.